Introduction
Despite major advances in monitoring and treatment of sepsis, the mortalities in cases of septic shock remain high. 1 It has been generally assumed that the pathogenesis of sepsis from Gram-positive organisms is similar enough to that of endotoxin shock from Gram-negative bacteria that the same basic mechanisms are involved. 2 It is now understood, however, that Gram-positive sepsis differs from Gram-negative sepsis in that the Gram-positive organisms often arise from skin, wounds, and softtissue structures rather than from enteric or genitourinary sources. 3 The polymyxin B-immobilized fibre (PMX-F) cartridge has been used in the management of sepsis patients in Japan since 1989 without critical adverse effects. 4, 5 We reported previously that PMX-F treatment effectively removes endotoxin in patients with sepsis caused by Gram-negative bacteria. 6, 7 Kodama et al. 4 reported that PMX-F treatment is effective in patients with methicillin-resistant Staphylococcus aureus (MRSA), suggesting that improved status may be due to the removal of a small amount of endotoxin in Grampositive or mixed infection, and that such reduction may prove effective in patients with toxic symptoms caused by endotoxin. The precise mechanisms involved are however still unclear.
Many investigators have examined the clinical efficacy of teicoplanin given daily for treatment of MRSA infections. 8, 9 Teicoplanin has low potential for causing oto-and nephrotoxicity and the red-man syndrome, and it has a longer half-life than does vancomycin, thus enabling once-daily administration. 10 In the present study, we evaluated the efficacy of PMX-F and teicoplanin in septic patients with MRSA.
Patients and methods
Sixty patients with MRSA sepsis (40 men and 20 women; mean age, 55.5 years) treated in our intensive care units were enrolled in the study during the first 24 h after the onset of sepsis. Patients were considered to have sepsis if they fulfilled the criteria proposed by the American College of Chest Physicians (ACCP)/Society of Critical Care Medicine (SCCM) Consensus Conference Committee.
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According to ACCP/SCCM definition, sepsis is manifested by two or more of the following features resulting from infection: (1) temperature b38 or 36 C, (2) heart rate b90 beats/min, (3) respiratory rate b20 breaths/min or PaCO 2`3 2 torr, and (4) white blood cell count b12 000/mm 3 or b10% immature forms. The Acute Physiology and Chronic Health Evaluation (APACHE) II score was determined for each patient. 12 Bacteraemia was diagnosed in 36 of the 60 patients by fever, chills or hypotension, and isolation of MRSA from at least two pretreatment blood cultures; catheter-associated infection was diagnosed in 18 patients based on fever, documented bacteraemia, and use of an intravascular access catheter in the absence of any other apparent source of infection. Diagnosis of soft tissue (18 patients) or bone infection (nine patients) required compatible radiographic studies and isolation of MRSA from a sample obtained by direct closed-space needle aspiration of the infected tissue; pneumonia (nine patients) was defined by the presence of new infiltrates on a chest X-ray and isolation of MRSA from sputum. Peritonitis (six patients) required a purulent exudate culture-positive for MRSA. Exclusion criteria were: treatment with steroids, immunosuppressive agents or nonsteroidal antiinflammatory agents.
This study was pre-approved by our human research ethics committees. Informed consent was obtained from each participant or a responsible family member.
Standard therapy included: administration of antibiotics (phosphomycin sodium, b-lactams including cefmetazole and arbekacin sulphate; these were used in combination), immunoglobulin infusions, vasoactive drugs, mechanical ventilatory support, corrective measures for metabolic abormalities and any other supportive therapy deemed necessary by the primary physician.
The 60 patients were randomly assigned to one of four treatments (A) PMX-F treatment (N 15), (B) teicoplanin treatment (N 15), (C) PMX-F and teicoplanin treatment (N 20), or (D) conventional treatment (N 10). Assignment to study groups was by means of sealed envelopes. There was blinding of allocation, treatment and outcome assessment.
PMX-F and the haemoperfusion column have been described previously. 4±7 To reduce the toxic effect of polymyxin B and derive benefit from the lipopolysaccharide (LPS) blocking property, polymyxin B was immobilized on to insoluble fibres creating a haemoperfusion column to use as an extracorporeal endotoxin removal device for the treatment of patients with sepsis. 4 ,5 PMX-F therapy was administered twice within a 24 h period (groups A and C). Access to the circulation for direct haemoperfusion with PMX-F was obtained by doublelumen catheter (Arrow International Inc., Reading, PA, USA) inserted into the femoral vein by Seldinger's method. Direct haemoperfusion was performed for 2 h at a flow rate of 80±100 mL/min. Blood endotoxin levels were determined by the Endospecy test (Seikagakukogyo, Tokyo, Japan) after pretreatment by the new perchloric acid method reported previously. 4 Teicoplanin (6 mg/kg) was administered by intravenous injection once daily for three days and then every other day for 14 days (groups B and C).
Data were expressed as mean AE SD. Results were analysed by one-way analysis of variance (ANOVA) and relative risk and absolute risk reduction were calculated. P`0.05 was accepted as statistically significant.
Results
Patient characteristics are shown for each treatment group in Table I . No significant differences were found with respect to age, sex, APACHE II score, systolic blood pressure, heart rate, temperature, white blood cell count, or C-reactive protein. MRSA was detected in all study patients. The sources of MRSA are shown in Table II . Blood endotoxin levels in groups A and C were significantly decreased after treatment (group A, from 16.2 AE 4.8 to 4.6 AE 2.4 pg/mL, P`0.05; group C, from 14.6 AE 5.4 to 3.6 AE 1.8 pg/mL, P`0.05). Levels in groups B and D, however, showed little difference after treatment (group B, from 15.0 AE 4.2 pg/mL to 13.2 AE 3.8 pg/mL and group D, from 14.6 AE 3.9 pg/mL to 13.8 AE 4.0 pg/mL). The survival rates were 53, 47, 90 and 20% in groups A, B, C and D, respectively. Statistical analysis is shown in Table III . Surviving patients were discharged within 60 days after treatment. The mean duration of stay was 44, 42, 28 and 56 days in groups A, B, C and D, respectively. Adverse events including hypersensitivity (erythema) were recognized in two patients (one patient in group B and one patient in group C). These were not seen in group A and group D.
Discussion
Sepsis is a major cause of death in critical care units worldwide, including Japan, and it consumes considerable healthcare resources. 2 The role of Gram-positive bacterial pathogens including MRSA in the occurrence of septic shock has received minimal attention because these organisms were thought to be quantitatively less important than Gramnegative bacteria as a cause of septic shock. 2 The prevalence of Gram-positive bacterial pathogens is on the increase because: (1) empiric antimicrobial regimens designed primarily against Gram-negative pathogens select for resistant Gram-positive pathogens, (2) long-term use of intravascular catheters is increasing, (3) the use of surgically implanted foreign materials is increasing, and (4) antibiotic resistance is increasing in Gram-positive organisms. Endotoxin is absent in Gram-positive bacteria, including MRSA. The cell wall contains a thick layer of peptidoglycan, which lies directly over the plasma membrane. The structural components of Gram-positive cell walls are able to mimic some of the properties of endotoxin in their ability to induce proinflammatory cytokine production in mononuclear cells. 13 Endotoxin is the principal component of Gram-negative bacteria responsible for initiating the process of sepsis. Endotoxaemia can sometimes occur in patients with Gram-positive bacteraemia, presumably as a consequence of damage to the integrity of the mucosal barrier in the gastrointestinal tract.
14 Despite conventional intensive care therapies, the prognosis in septic patients is still poor. Apheresis therapies, which use more selective adsorption techniques, can lower the extent of toxins and cytokines in blood. 15 Various apheresis techniques have been suggested for extracorporeal endotoxin removal. The PMX cartridge has been safely used without adverse effects. We reported previously that PMX-F was effective in patients with Gramnegative bacterial sepsis. 6, 7 In the present study, endotoxaemia occurred in septic patients with MRSA, and PMX-F treatment reduced plasma endotoxin levels in these patients. The survival rate with PMX-F treatment was higher than that with conventional treatment. In vitro, polymyxin-B shows antimicrobial activity against MRSA. 16 Jaber et al. 17 reported the ability of polymyxin-B to inhibit the biological activity of S. aureus lipoteichoic acids, and the ability of a PMX-20R column to remove cytokine-inducing bacterial products other than lipopolysaccharide from 10% human plasma solution containing S. aureus. Iwama et al. 18 reported PMX-F to be effective in a patient with sepsis due to Grampositive infection. Small amounts of endotoxin play a key role in the presence of other inflammatory cytokines and mediators in the development of the symptoms of sepsis. Similar findings have been observed with endotoxins and toxic shock syndrome toxin (TSST)-1. The toxicity of TSST-1 in staphylococcal infection increases by 50 000 times in the presence of endotoxin. 19 Miwa et al. 20 have developed a sensitive and specific ELISA that enables quantitation of TSST-1. In preliminary studies of sepsis patients with MRSA infection, we recognized that PMX-F reduced TSST-1 concentrations, in part due to the reduction by PMX-F of endotoxin observed in the present study (data not shown).
Teicoplanin is a glycopeptide antibiotic available in Europe and Japan that is active against MRSA. 8, 9 Some investigators reported that teicoplanin is effective in vascular access-associated sepsis, softtissue infections, osteomyelitis, and pneumonia caused by MRSA. 8, 10 Recently, Otsuka et al.
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reported that the antibacterial activity of teicoplanin was attenuated by combination with flomoxef, panipenem or cefmetazole. Several clinical trials have assessed the efficacy of teicoplanin given once daily at doses of 6 mg/kg. 8, 22 Bantar et al. 8 reported the efficacy and pharmacodynamics of teicoplanin, given daily at 6 mg/kg during the first three days and then on alternate days, for treatment of MRSA. We used this protocol in the present study. Vancomycin is considered the agent of choice for Gram-positive infections, and its use has increased substantially worldwide. Rolston et al. 10 reported that teicoplanin and vancomycin show equivalent efficacy and tolerance in septicaemia caused by Gram-positive pathogens. Teicoplanin offers some potential advantages over vancomycin, however, including a favourable toxicity profile and a long half-life. 23, 24 In preliminary studies, we compared the survival rate and adverse events between teicoplanin and vancomycin in 20 MRSA-septic patients (N 10 in each group). The survival rate was 50% in teicoplanin-treated patients, and 30% in vancomycintreated patients. Adverse events including hypersensitivity, hepatotoxicity and nephrotoxicity in vancomycin-treated patients were more than those in the teicoplanin-treated group. Therefore, we selected teicoplanin instead of vancomycin in the present study.
Knapp et al. 25 reported that only soluble ELAM-1 is a useful early parameter in predicting outcome of patients with Gram-positive sepsis and that soluble VCAM-1 could not be used as an early prognostic parameter. Staphylococcal enterotoxins are described as`superantigens' that stimulate T-cell activation and release of T-cell-derived cytokines including interleukins, tumour necrosis factor-alpha (TNF-alpha) as well as interferon-gamma. 26 We are now studying the effect of PMX-F teicoplanin treatment on these factors. In addition, Yoh et al.
with PMX-F and teicoplanin reduced urinary protein excretion from 3.2 AE 1.6 to 0.6 AE 0.3 g/day (data not shown). Therefore, this combination therapy may be effective in MRSA-related glomerulonephritis. Further studies of MRSA-related glomerulonephritis are now in progress.
Our results show that PMX-F and teicoplanin in combination is more effective in patients with sepsis caused by MRSA than is treatment with PMX-F or teicoplanin alone.
